España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

octapharma s.a. - factor von willebrand humano; factor viii humano - polvo y disolvente para soluciÓn inyectable - 1.000 ui/1.000 ui - factor von willebrand humano 1000 ui; factor viii humano 1000 ui - factor von willebrand y factor viii de la coagulación en combinación

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

octapharma s.a. - factor von willebrand humano; factor viii humano - polvo y disolvente para soluciÓn inyectable - 500 ui/500 ui - factor von willebrand humano 500 ui; factor viii humano 500 ui - factor von willebrand y factor viii de la coagulación en combinación

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

lfb biomedicaments - factor von willebrand humano - polvo y disolvente para soluciÓn inyectable - 1.000 ui - factor von willebrand humano 1000 ui - factor von willebrand

Unión Europea - español - EMA (European Medicines Agency)

bpl bioproducts laboratory gmbh - humanos de la coagulación factor x - deficiencia de factor x - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex está indicado para el tratamiento y la profilaxis de episodios hemorrágicos y para el tratamiento perioperatorio en pacientes con deficiencia hereditaria de factor x.. coagadex está indicado en todos los grupos de edad.

Unión Europea - español - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Venezuela - español - Instituto Nacional de Higiene

corporacion colimodio c.a - factor viii antihemofilico humano - polvo liofilizado para sol. inyectable - 250 ui/ml (a1)

Venezuela - español - Instituto Nacional de Higiene

lepsis, s.a. - factor ix de coagulacion - polvo liofilizado para sol. inyectable - 500 u.i.

Venezuela - español - Instituto Nacional de Higiene

schering-plough, c.a.caracas - factor estimulante de granulocitos y macrofagos - polvo liofilizado para sol. inyectable - 500 mcg/vial

Venezuela - español - Instituto Nacional de Higiene

schering-plough, c.a.caracas - factor estimulante de granulocitos y macrofagos - polvo liofilizado para sol. inyectable - 50 mcg/vial

Venezuela - español - Instituto Nacional de Higiene

schering plough c.a., venezuela - factor estimulante de granulocitos y macrofagos - polvo liofilizado para sol. inyectable - 700 mcg/ vial